- $603.76m
- $254.03m
- 48
- 26
- 33
- 27
Annual cashflow statement for Replimune, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.6 | -80.9 | -118 | -174 | -216 |
| Depreciation | |||||
| Non-Cash Items | 6.95 | 14.3 | 26.5 | 28.7 | 22.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -15.4 | 3.51 | 7.24 | 15.1 | 5.48 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.6 | -61.4 | -82.2 | -128 | -185 |
| Capital Expenditures | -6.54 | -2.39 | -2.34 | -2.27 | -5.66 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.31 | -186 | 0.53 | -140 | 103 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.23 | -189 | -1.81 | -143 | 97.2 |
| Financing Cash Flow Items | -0.355 | -0.895 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 100 | 372 | 6.6 | 311 | 16.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 34.2 | 123 | -76.6 | 40.6 | -72.1 |